Home » GLAXOSMITHKLINE SETTLES INFLATION CLAIM
GLAXOSMITHKLINE SETTLES INFLATION CLAIM
GlaxoSmithKline Inc. has agreed to pay more than $41 million in restitution to end claims by more than 40 states that it inflated the prices of drugs used by cancer patients and others.
Business Week
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct